Our research group aims at democratizing retinal gene therapy by developing innovative, cost-effective solutions tailored for eye diseases. We are investigating cutting-edge mRNA technology to address both inherited and chronic retinal conditions. By integrating in vitro transcribed mRNA systems with advanced biomaterials, we aim to create patient-friendly therapies that are accessible to people worldwide, transforming the landscape of eye care and improving lives on a global scale.